|
[Vol.34 No.2 contents]
Japanese/English
Full Text of this Articlein Japanese PDF (439K) |
| ArticleTitle | Disease modifying drugs for Alzheimer's disease |
| Language | J |
| AuthorList | Atsushi Iwata |
| Affiliation | Department of Neurology, The University of Tokyo |
| Publication | Japanese Journal of Neuropsychology: 34 (2), 113-117, 2018 |
| Received | |
| Accepted | |
| Abstract | Drug discovery has been attempted on amyloid β and tau protein that underlie the pathological level of Alzheimer's disease. However, there have not been any drug that has succeeded. Various causes are considered for the reason. One of the biggest problem is the difficulty of pathological diagnosis of neurodegeneration since they are hidden beneath the thick skull. The second is the fact that pathological process of Alzheimer's disease undergoes for a long period of time, nearly 20 years. Based on these facts, the design of the clinical trial and the design of the medicine are improving, and it is getting closer to success step by step. |
| Keywords | Alzheimer's disease, amyloid β, preclinical |
Copyright © 2002 NEUROPSYCHOLOGY ASSOCIATION OF JAPAN All rights reserved
http://www.neuropsychology.gr.jp/